Platelet-derived growth factor receptor kinase inhibitor AG-1295 promotes osteoblast differentiation in MC3T3-E1 cells via the Erk pathway

BioScience Trends

Volumn 6, Issue 3, 2012, Pages 130-135

  Zhang, Yongying ^a   Cui, Yazhou ^a   Luan, Jing ^a   Zhou, Xiaoyan ^a   Zhang, Genglin ^a   Han, Jinxiang ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

AG 1295; Extracellular signal regulated kinases 1 and 2; Matrix mineralization; Platelet derived growth factor receptor beta

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7-DIMETHOXY-2-PHENYLQUINOXALINE; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE 2, MOUSE; ASCORBIC ACID; BETA-GLYCEROPHOSPHORIC ACID; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; DEXAMETHASONE; GLYCEROL 2 PHOSPHATE; GLYCEROPHOSPHATE; OSTEOCALCIN; OSTERIX PROTEIN, MOUSE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RUNX2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TYRPHOSTIN;

ANIMAL; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL LINE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; OSTEOBLAST; PHOSPHORYLATION; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ALKALINE PHOSPHATASE; ANIMALS; ASCORBIC ACID; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE; COLLAGEN TYPE I; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLYCEROPHOSPHATES; MAP KINASE SIGNALING SYSTEM; MICE; OSTEOBLASTS; OSTEOCALCIN; OSTEOGENESIS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TRANSCRIPTION FACTORS; TYRPHOSTINS;

EID: 84866793480     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2012.v6.3.130     Document Type: Article

References (25)

1. Moenning A, Jager R, Egert A, Kress W, Wardelmann E, Schorle H. Sustained platelet-derived growth factor receptor alpha signaling in osteoblasts results in craniosynostosis by overactivating the phospholipase C-gamma pathway. Mol Cell Biol. 2009; 29:881-891.
2. Klinghoffer RA, Duckworth B, Valius M, Cantley L, Kazlauskas, A. Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol Cell Biol. 1996; 16:5905-5914.
3. Valius M, Bazenet C, Kazlauskas A. Tyrosines 1021 and 1009 are phosphorylation sites in the carboxy terminus of the platelet-derived growth factor receptor beta subunit and are required for binding of phospholipase C gamma and a 64-kilodalton protein, respectively. Mol Cell Biol. 1993; 13:133-143.
4. Yu J, Deuel TF, Kim HR. Platelet-derived growth factor (PDGF) receptor-alpha activates c-Jun NH2-terminal kinase-1 and antagonizes PDGF receptor-beta -induced phenotypic transformation. J Biol Chem. 2000; 275:19076-19082.
5. Kyono A, Avishai N, Ouyang Z, Landreth GE, Murakami S. FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation. J Bone Miner Metab. 2012; 30:19-30.
6. Caplan AI, Correa D. PDGF in bone formation and regeneration: New insights into a novel mechanism involving MSCs. J Orthop Res. 2011; 29:1795-1803.
7. Vordemvenne T, Paletta JR, Hartensuer R, Pap T, Raschke MJ, Ochman S. Cooperative effects in differentiation and proliferation between PDGF-BB and matrix derived synthetic peptides in human osteoblasts. BMC Musculoskelet Disord. 2011; 12:263.
8. Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, Boxberger S, Bornhäuser M. Inhibition of plateletderived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif. 2007; 40:355-366.
9. Hock JM, Canalis E. Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology. 1994. 134:1423-1428.
10. Kubota K, Sakikawa C, Katsumata M, Nakamura T, Wakabayashi K. Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res. 2002; 17:257-265.
11. O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, Watson M, Cornish J, Browett P, Grey A. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res. 2007; 22:1679-1689.
12. Tokunaga A, Oya T, Ishii Y, Motomura H, Nakamura C, Ishizawa S, Fujimori T, Nabeshima Y, Umezawa A, Kanamori M, Kimura T, Sasahara M. PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone Miner Res. 2008; 23:1519-1528.
13. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC. Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008; 111:2538-2547.
14. Kumar A, Salimath BP, Stark GB, Finkenzeller G. Platelet-derived growth factor receptor signaling is not involved in osteogenic differentiation of human mesenchymal stem cells. Tissue Eng Part A. 2010; 16:983-993.
15. Chorny M, Fishbein I, Danenberg HD, Golomb G. Study of the drug release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink methods. J Control Release. 2002; 83:401-414.
16. Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol. 1983. 96:191-198.
17. Akamine R, Yamamoto T, Watanabe M, Yamazaki N, Kataoka M, Ishikawa M, Ooie T, Baba Y, Shinohara Y. Usefulness of the 5' region of the cDNA encoding acidic ribosomal phosphoprotein P0 conserved among rats, mice, and humans as a standard probe for gene expression analysis in different tissues and animal species. J Biochem Biophys Methods. 2007; 70:481-486.
18. Kovalenko M, Gazit A, Böhmer A, Rorsman C, Rönnstrand L, Heldin CH, Waltenberger J, Böhmer FD, Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994; 54:6106-6114.
19. Karck M, Meliss R, Hestermann M, Mengel M, Pethig K, Levitzki A, Banai S, Golomb G, Fishbein I, Chorny M, Haverich A. Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. Transplantation. 2002; 74:1335-1341.
20. Nemoto E, Shimonishi M, Nitta Y, Shimauchi H. The involvement of platelet-derived growth factor receptors and insulin-like growth factor-I receptors signaling during mineralized nodule formation by human periodontal ligament cells. J Periodontal Res. 2004; 39:388-397.
21. Higuchi C, Myoui A, Hashimoto N, Kuriyama K, Yoshioka K, Yoshikawa H, Itoh K. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res.2002; 17:1785-1794.
22. Chaudhary LR, Avioli LV. Extracellular-signal regulated kinase signaling pathway mediates downregulation of type I procollagen gene expression by FGF-2, PDGFBB, and okadaic acid in osteoblastic cells. J Cell Biochem. 2000; 76:354-359.
23. Foster BL, Nociti FH Jr, Swanson EC, Matsa-Dunn D, Berry JE, Cupp CJ, Zhang P, Somerman MJ. Regulation of cementoblast gene expression by inorganic phosphate in vitro. Calcif Tissue Int. 2006; 78:103-112.
24. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. Am J Physiol Endocrinol Metab. 2009; 296: E139-E146.
25. Omoteyama K, Takagi M. The effects of Sp7/Osterix gene silencing in the chondroprogenitor cell line, ATDC5. Biochem Biophys Res Commun. 2010; 403:242-246.